LifeStance Health Group, Inc. — Q2 2021 Form 10-Q
Reporting period: Quarter and six months ended June 30, 2021. Unless stated otherwise, dollar amounts below are in millions; financial statements are unaudited. The company provides outpatient mental health services through owned subsidiaries and affiliated practices.
Business context and reporting period
LifeStance completed its IPO in June 2021 and reported nearly 4,000 clinicians as of June 30. It also completed 10 practice acquisitions in Q2 and 11 in the first half. Comparisons with 2020 require caution: the 2020 statements are split between predecessor and successor periods following the May 2020 acquisition, and the accounting basis changed, so the periods are not directly comparable.
Financial results and liquidity
| Metric | Q2 2021 | Six months 2021 |
|---|---|---|
| Revenue | $160.5 | $303.7 |
| Operating loss | $(47.0) | $(47.9) |
| Net loss | $(70.0) | $(78.7) |
| Center Margin (non-GAAP) | $51.2 | $95.2 |
| Adjusted EBITDA (non-GAAP) | $14.5 | $27.1 |
| Operating cash flow | $(7.0) for the first half |
Q2 revenue comprised $159.4 of patient services and $1.2 of nonpatient revenue. Center Margin was approximately 31.9% of revenue and Adjusted EBITDA approximately 9.1%; both are company-defined non-GAAP measures. Commercial payors accounted for 92% of Q2 revenue. The five largest commercial payors represented 62%, and the largest represented 18%.
At June 30, cash and cash equivalents were $276.2, compared with $18.8 at year-end 2020. Gross debt principal was $161.9 (balance-sheet long-term debt, net of current portion and issuance costs, was $157.1); no revolving-loan balance was outstanding. First-half investing cash outflow was $70.9, including $39.1 for acquisitions and $31.8 for property and equipment. Financing cash inflow was $335.3, primarily reflecting IPO proceeds and debt activity. The company reported $115.0 of future minimum third-party lease payments and $11.2 of related-party lease payments.
Material changes and unusual items
- The IPO generated $548.9 of net proceeds in the financial statements. The company used proceeds in part to prepay $294.0 of borrowings and recorded a $14.4 debt-extinguishment charge within interest expense.
- Q2 general and administrative expense was $85.5, including $29.5 of stock and unit-based compensation, primarily related to IPO-linked award conversions and grants, and a $10.0 foundation endowment. These items materially affected reported operating results.
- Debt principal declined from $373.8 at December 31, 2020 to $161.9 at June 30, 2021. The company said it was in compliance with its debt covenants at quarter-end.
- Reported 2020 periods are not a clean comparable baseline; the filing does not provide a directly comparable Q2 year-over-year growth rate.
Outlook, commentary, and risks
Management said existing cash was expected to fund operating and capital needs for at least the next 12 months, while cautioning that growth, acquisitions, and expansion could increase capital needs and additional financing might be required. No specific revenue or earnings guidance is provided. Management described continued clinician recruitment, center openings, acquisitions, and expansion of payor and provider partnerships as growth priorities.
- Management said COVID-19 had not materially affected the reported results and viewed increased attention to mental health as a potential long-term demand driver. It noted uncertainty about how long pandemic-related telehealth regulatory changes will remain in effect.
- Risks include reimbursement-rate pressure, payor concentration, healthcare regulation and affiliated-practice arrangements, execution of rapid growth and acquisitions, competition, data security, and floating-rate debt exposure. A 100-basis-point interest-rate change was estimated to affect annual interest expense by $1.6.
- Disclosure controls and procedures were deemed ineffective at June 30 because of previously identified material weaknesses in accounting resources, financial reporting controls, and IT general controls. Remediation efforts were ongoing.
- The company expected adoption of lease accounting standard ASC 842 to materially affect its balance sheet. It disclosed ordinary-course legal matters and healthcare regulatory exposure but did not expect known litigation to have a material adverse effect.
Important facts for investors to verify
- Reconcile the IPO proceeds figures: the financial statements report $548.9 of net proceeds, while Part II describes approximately $558.0; confirm the distinction and final amount.
- Assess the sustainability of positive Adjusted EBITDA and Center Margin against GAAP losses, cash used in operations, and recurring corporate costs.
- Review the scale and timing of stock-compensation expense and future dilution; the filing reports $450.9 of unrecognized compensation expense at June 30.
- Monitor payor concentration, reimbursement rates, acquisition integration and contingent consideration, and the company’s ability to maintain covenant compliance and fund expansion.
- Track remediation of the material weaknesses and the balance-sheet effect of lease accounting adoption.